Tag Archives: ADC target

The TROP2 protein comprises four distinct segments, including 323 amino acids: 1-26 amino acids as a hydrophobic signal peptide, 27-274 amino acids as the extracellular domain, 275-297 amino acids as the transmembrane domain, and 298-323 amino acids as the cytoplasmic tail.

Advances in TROP2-ADC Drug Research

Tumor-Associated Calcium Signal Transducer 2 (TROP2), also known as TACSTD2 and EGP-1, is a surface antigen found in numerous solid tumors. It has become a pivotal target for pharmaceutical giants spurring a race in drug development in the world. Currently, TROP2-targeting biopharmaceuticals are predominantly concentrated in the Antibody-Drug Conjugate (ADC). Based on incomplete statistics, there are 11 TROP2-targeting […]

Blog 2023-11-10
CEACAMs, short for carcinoembryonic antigen-related cell adhesion molecules, constitute a family of cell surface glycoproteins encompassing 12 distinct members: CEACAM1, CEACAM3, CEACAM4, CEACAM5, CEACAM6, CEACAM7, CEACAM8, CEACAM16, CEACAM18, CEACAM19, CEACAM20 and CEACAM21. These proteins are classified within the immunoglobulin superfamily of adhesion molecules, and they share structural similarities with unique variations.

CEACAM5, an emerging target for cancer therapy

Human carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), initially discovered in colon cancer by Gold and Freeman in 1965 [1] [2], has long served as a pivotal tumor marker for clinical detection and diagnosis of colorectal cancer. Recent advancements in CEACAM5 research have unveiled its potential as a target for developing novel cancer therapeutics. Notably, […]

Blog 2023-09-19
CLDN6 has four transmembrane domains, a short cytoplasmic N-terminus, a C-terminal cytoplasmic domain, two extracellular domains (larger ECL1 and a smaller ECL2) and a short intracellular loop. ECL1 and the PDZ-binding domain at the cytoplasmic C-terminus are characteristic domains of CLDNs.

CLDN6, the next promising target for solid tumor therapy after ClDN18.2?

In June 2023, BioNTech presented the first human trial data of BNT211 at the American Society of Clinical Oncology (ASCO). BNT211 is a CLDN-6-targeting CAR-T cell therapy in combination with a CLDN6-encoding mRNA vaccine (CARVac). mRNA vaccines stimulate the expansion of CAR-T cells in the patients’ body by inducing the expression of CLDN6 on the surface of antigen-presenting cells, […]

Blog ,, 2023-08-17